 | |
| Clinical data | |
|---|---|
| Trade names | Neo-Cobefrine |
| Other names | Levonordefrin; α-Methylnorepinephrine; (–)-3,4-Dihydroxynorephedrine; 3,4,β-Trihydroxy-α-methylphenethylamine; 3,4,β-Trihydroxyamphetamine |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.113.606 |
| Chemical and physical data | |
| Formula | C9H13NO3 |
| Molar mass | 183.207 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Corbadrine, sold under the brand name Neo-Cobefrine and also known as levonordefrin and α-methylnorepinephrine, is a catecholamine sympathomimetic used as a topical nasal decongestant and vasoconstrictor in dentistry in the United States.[1][2][3] It is usually used in a pre-mixed solution with local anesthetics, such as mepivacaine.[4]
The drug acts as a non-selective agonist of the α1-, α2-, and β-adrenergic receptors.[5][6][7] It is said to have preferential activity at the α2-adrenergic receptor.[5][7]
Corbadrine is also a metabolite of the antihypertensive drug methyldopa and lays a role in its pharmacology and effects.[8]
Pharmacology
Pharmacokinetics
Corbadrine is metabolized primarily by catechol O-methyltransferase (COMT).[7]
Chemistry
Corbadrine, also known as 3,4,β-trihydroxy-α-methylphenethylamine or as 3,4,β-trihydroxyamphetamine, as well as α-methylnorepinephrine or (–)-3,4-dihydroxynorephedrine, is a substituted phenethylamine and amphetamine derivative.[1][3]
Analogues of corbadrine include α-methyldopamine, dioxifedrine (3,4-dihydroxyephedrine; α-methylepinephrine), dioxethedrin (3,4-dihydroxy-N-ethylnorephedrine; α-methyl-N-ethylnorepinephrine), and hydroxyamphetamine (4-hydroxyamphetamine; α-methyltyramine).
Society and culture
Names
Corbadrine is the generic name of the drug and its INN.[1][3][2] It is also known as levonordefrin, which is its USAN.[1][3][2] Synonyms of corbadrine include α-methylnorepinephrine and (–)-3,4-dihydroxynorephedrine.[9] The drug has been sold under the brand name Neo-Cobefrine.[3]
References
- ^ a b c d Elks, J. (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. p. 55. ISBN 978-1-4757-2085-3. Retrieved 30 August 2024.
- ^ a b c Morton I, Morton IK, Hall JM (31 October 1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 164–. ISBN 978-0-7514-0499-9.
- ^ a b c d e Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 275–. ISBN 978-3-88763-075-1.
- ^ "DailyMed — Search results for levonordefrin". DailyMed. Retrieved 20 February 2016.
- ^ a b Logothetis, D.D. (2016). Local Anesthesia for the Dental Hygienist. Elsevier Health Sciences. p. 46. ISBN 978-0-323-43050-0. Retrieved 30 August 2024.
- ^ Abraham, Donald J. (15 January 2003). Burger's Medicinal Chemistry and Drug Discovery. Wiley. doi:10.1002/0471266949.bmc093. ISBN 978-0-471-26694-5.
- ^ a b c Naftalin LW, Yagiela JA (October 2002). "Vasoconstrictors: indications and precautions". Dent Clin North Am. 46 (4): 733–746, ix. doi:10.1016/s0011-8532(02)00021-6. PMID 12436828.
- ^ Sjoerdsma A, Vendsalu A, Engelman K (October 1963). "Studies on the Metabolism and Mechanism of Action of Methyldopa". Circulation. 28 (4): 492–502. doi:10.1161/01.CIR.28.4.492. PMID 14068757.
- ^ "Levonordefrin". PubChem. Retrieved 30 August 2024.
External links
- Nordefrin at the U.S. National Library of Medicine Medical Subject Headings (MeSH)